Pharmacodynamic effect of clopidogrel therapy and switching to cilostazol in patients with the CYP2C19 loss-of-function allele (ACCEL-SWITCH) study

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 8, 2012, Pages 1685-1688

  Jeong, Y H ^a,b   Park, Y ^a   Muse, W C ^b   Kwon, T J ^a   Koh, J S ^a   Hwang, S J ^a   Kwak, C H ^a   Hwang, J Y ^a  

^a Gyeongsang National University   (South Korea)

^b SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; CYTOCHROME P450 2C19;

ALLELE; ANTICOAGULANT THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ELUTING STENT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENE FUNCTION; GENETIC VARIABILITY; GENOTYPE; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LETTER; OBSERVATIONAL STUDY; PRIORITY JOURNAL; THROMBOCYTE FUNCTION; THROMBOSIS;

ANGIOPLASTY, BALLOON, CORONARY; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; ASPIRIN; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; PHENOTYPE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; TETRAZOLES; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84865227532     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04788.x     Document Type: Letter

References (13)

1. Räber L, Magro M, Stefanini GG, Kalesan B, van Domburg RT, Onuma Y, Wenaweser P, Daemen J, Meier B, Jüni P, Serruys PW, Windecker S. Very late coronary stent thrombosis of a newer generation everolimus-eluting stent compared with early generation drug-eluting stents: a prospective cohort study. Circulation 2012; 125: 1110-21.
2. Inoue T, Croce K, Morooka T, Sakuma M, Node K, Simon DI. Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv 2011; 4: 1057-66.
3. Jeong YH, Tantry US, Bliden KP, Gurbel PA. Cilostazol to overcome high on-treatment platelet reactivity in korean patients treated with clopidogrel and calcium-channel blocker. Circ J 2011; 75: 2534-6.
4. Kawabe-Yako R, Masaaki I, Masuo O, Asahara T, Itakura T. Cilostazol activates function of bone marrow-derived endothelial progenitor cell for re-endothelialization in a carotid balloon injury model. PLoS One 2011; 6: e24646.
5. Tamhane U, Meier P, Chetcuti S, Chen KY, Rha SW, Grossman MP, Gurm H. Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials. EuroIntervention 2009; 5: 384-93.
6. Lee SW, Park SW, Yun SC, Kim YH, Park DW, Kim WJ, Lee JY, Lee CW, Hong MK, Kim JJ, Park SJ. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). Am Heart J 2010; 159: 284-91.e1.
7. Ahn Y, Jeong MH, Jeong JW, Kim KH, Ahn TH, Kang WC, Park CG, Kim JH, Chae IH, Nam CW, Hur SH, Bae JH, Kim KY, Oh SK. Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients - clilostazol for diabetic patients in drug-eluting stent (CIDES) trial. Circ J 2008; 72: 35-9.
8. Jeong YH, Tantry US, Kim IS, Koh JS, Kwon TJ, Park Y, Hwang SJ, Bliden KP, Kwak CH, Hwang JY, Gurbel PA. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. Circ Cardiovasc Interv 2011; 4: 585-94.
9. Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H, Nishikawa H, Hiasa Y, Muramatsu T, Meguro T, Inoue N, Honda H, Hayashi Y, Miyazaki S, Oshima S, Honda T, Shiode N, Namura M, Sone T, Nobuyoshi M, et al., j-Cypher Registry Investigators. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 2009; 119: 987-95.
10. Kim JS, Lee KS, Kim YI, Tamai Y, Nakahata R, Takami H. A randomized crossover comparative study of aspirin, cilostazol and clopidogrel in normal controls: analysis with quantitative bleeding time and platelet aggregation test. J Clin Neurosci 2004; 11: 600-2.
11. Hiratsuka M, Hinai Y, Sasaki T, Konno Y, Imagawa K, Ishikawa M, Mizugaki M. Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol. Drug Metab Dispos 2007; 35: 1730-2.
12. Hayashi H, Sudo T. Effects of the cAMP-elevating agents cilostamide, cilostazol and forskolin on the phosphorylation of Akt and GSK-3beta in platelets. Thromb Haemost 2009; 102: 327-35.
13. Kim HS. Adjunctive cilostazol vs. double-dose clopidogrel after PCI with drug eluting stent: the HOST-ASSURE randomized trial. Presented at American College of Cardiology Meeting 2012 at Chicago, USA.